BR0203172A - Agentes terapêuticos para acondroplasia - Google Patents
Agentes terapêuticos para acondroplasiaInfo
- Publication number
- BR0203172A BR0203172A BR0203172-8A BR0203172A BR0203172A BR 0203172 A BR0203172 A BR 0203172A BR 0203172 A BR0203172 A BR 0203172A BR 0203172 A BR0203172 A BR 0203172A
- Authority
- BR
- Brazil
- Prior art keywords
- therapeutic agents
- achondroplasia
- fgfr3
- mutations
- achondroplasia caused
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2242—Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
"AGENTES TERAPêUTICOS PARA ACONDROPLASIA". A presente invenção visa fornecer novos agentes terapêuticos para acondroplasia causada por mutações em FGFR3. São divulgados agentes terapêuticos para acondroplasia causada pela inibição de crescimento da cartilagem resultante de mutações no gene para o receptor do fator de crescimento de fibroblasto 3 (FGFR3), que compreende uma substância que ativa a guanilil ciclase B (GC-B) como um ingrediente ativo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001301586A JP2003104908A (ja) | 2001-09-28 | 2001-09-28 | 軟骨無形成症治療剤 |
JP2001310322A JP4252746B2 (ja) | 2001-10-05 | 2001-10-05 | 軟骨無形成症治療剤 |
Publications (3)
Publication Number | Publication Date |
---|---|
BR0203172A true BR0203172A (pt) | 2003-09-09 |
BRPI0203172B1 BRPI0203172B1 (pt) | 2016-02-23 |
BRPI0203172B8 BRPI0203172B8 (pt) | 2021-05-25 |
Family
ID=26623312
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0203172A BRPI0203172B8 (pt) | 2001-09-28 | 2002-08-13 | composição farmacêutica para acondroplasia |
Country Status (3)
Country | Link |
---|---|
US (2) | US6743425B2 (pt) |
BR (1) | BRPI0203172B8 (pt) |
CA (2) | CA2398030C (pt) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL142118A0 (en) * | 2001-03-20 | 2002-03-10 | Prochon Biotech Ltd | Method and composition for treatment of skeletal dysplasias |
US8137397B2 (en) * | 2004-02-26 | 2012-03-20 | Boston Scientific Scimed, Inc. | Medical devices |
EP1743653A4 (en) * | 2004-03-31 | 2009-09-30 | Kazuwa Nakao | COMPOSITION FOR INCREASING BODY SIZE |
CN1960758B (zh) * | 2004-03-31 | 2014-10-22 | 中外制药株式会社 | 关节炎的治疗剂或预防剂 |
EP1759001B1 (en) | 2004-04-21 | 2011-04-13 | Enobia Pharma Inc. | Bone delivery conjugates and method of using same to target proteins to bone |
ES2278519B1 (es) * | 2005-09-02 | 2008-09-16 | Fundacion Magar | Tratamiento de la acondroplasia por la administracion de dinucleotidos. |
JP2011504506A (ja) * | 2007-11-21 | 2011-02-10 | バイオマリン ファーマシューティカル インコーポレイテッド | C型ナトリウム利尿ペプチドの変異体 |
KR102225470B1 (ko) | 2009-05-20 | 2021-03-10 | 바이오마린 파머수티컬 인크. | 씨형 나트륨이뇨 펩티드의 변이체 |
WO2011153531A1 (en) | 2010-06-04 | 2011-12-08 | University Of South Florida | Method of treating skeletal dysplasias using vessel dilator |
CA2823066A1 (en) | 2010-12-27 | 2012-07-05 | Alexion Pharma International Sarl | Compositions comprising natriuretic peptides and methods of use thereof |
CA2852874A1 (en) | 2011-10-19 | 2013-04-25 | Alexion Pharma Holding | Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof |
WO2013088191A1 (en) | 2011-12-12 | 2013-06-20 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Antagonist of the fibroblast growth factor receptor 3 (fgfr3) for use in the treatment or the prevention of skeletal disorders linked with abnormal activation of fgfr3 |
US10052366B2 (en) | 2012-05-21 | 2018-08-21 | Alexion Pharmaceuticsl, Inc. | Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof |
KR20160002681A (ko) | 2013-01-16 | 2016-01-08 | 인썸(인스티튜트 내셔날 드 라 싼테 에 드 라 리셰르셰메디칼르) | 골격 성장 지연 질환의 예방 또는 치료에 사용하기 위한 용해성 섬유아세포 성장 인자 수용체 3(fgr3) 폴리펩티드 |
ES2529369B2 (es) * | 2013-07-09 | 2015-10-14 | Ocupharm Diagnostics S.L. | Uso del compuesto 2,5-dihidroxibencenosulfonato de calcio (calcio dobesilato) para la elaboracion de un medicamento para el tratamiento de la acondroplasia |
US10822596B2 (en) | 2014-07-11 | 2020-11-03 | Alexion Pharmaceuticals, Inc. | Compositions and methods for treating craniosynostosis |
MX2017007392A (es) | 2014-12-05 | 2019-01-24 | Alexion Pharma Inc | Tratamiento de convulsiones con fosfatasa alcalina recombinante. |
JP6868561B2 (ja) | 2015-01-28 | 2021-05-12 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | アルカリホスファターゼ欠損を有する被験者を治療する方法 |
AU2016308624B2 (en) | 2015-08-17 | 2022-06-23 | Alexion Pharmaceuticals, Inc. | Manufacturing of alkaline phosphatases |
JP6868617B2 (ja) | 2015-09-28 | 2021-05-12 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | 低ホスファターゼ血症の組織非特異的アルカリホスファターゼ(tnsalp)酵素補充療法に有効な投薬計画の特定 |
EP3368062A4 (en) | 2015-10-30 | 2019-07-03 | Alexion Pharmaceuticals, Inc. | METHODS OF TREATING CRANIOSYNOSTOSIS IN A PATIENT |
EP3400065A1 (en) | 2016-01-08 | 2018-11-14 | Ascendis Pharma Growth Disorders A/S | Controlled-release cnp agonists with reduced side-effects |
AU2017205693B2 (en) | 2016-01-08 | 2022-03-31 | Ascendis Pharma Growth Disorders A/S | Controlled-release CNP agonists with low initial NPR-B activity |
KR20180100624A (ko) | 2016-01-08 | 2018-09-11 | 아센디스 파마 그로우쓰 디스오더스 에이/에스 | 증가된 nep 안정성을 갖는 제어 방출성 cnp 작용제 |
KR102373744B1 (ko) | 2016-01-08 | 2022-03-15 | 아센디스 파마 그로우쓰 디스오더스 에이/에스 | 낮은 npr-c 결합을 갖는 제어 방출성 cnp 작용제 |
CA3007979C (en) | 2016-01-08 | 2023-12-19 | Ascendis Pharma Growth Disorders A/S | Cnp prodrugs with carrier attachment at the ring moiety |
US11065306B2 (en) | 2016-03-08 | 2021-07-20 | Alexion Pharmaceuticals, Inc. | Methods for treating hypophosphatasia in children |
EP3436052A4 (en) | 2016-04-01 | 2019-10-09 | Alexion Pharmaceuticals, Inc. | TREATMENT OF MUSCLE WEAKNESS USING ALKALINE PHOSPHATASES |
EP3436020A4 (en) | 2016-04-01 | 2019-12-25 | Alexion Pharmaceuticals, Inc. | METHOD FOR TREATING HYPOPHOSPHATASIE IN TEENS AND ADULTS |
US10988744B2 (en) | 2016-06-06 | 2021-04-27 | Alexion Pharmaceuticals, Inc. | Method of producing alkaline phosphatase |
MX2018016257A (es) | 2016-07-07 | 2019-11-21 | Therachon Sas | Polipéptidos del receptor 3 del factor de crecimiento de fibroblastos solubles (sfgfr3) y usos de los mismos. |
US11116821B2 (en) | 2016-08-18 | 2021-09-14 | Alexion Pharmaceuticals, Inc. | Methods for treating tracheobronchomalacia |
SG10202111952PA (en) | 2016-09-29 | 2021-12-30 | Ascendis Pharma Growth Disorders As | Combination therapy with controlled-release cnp agonists |
EP3600383A4 (en) | 2017-03-31 | 2020-10-28 | Alexion Pharmaceuticals, Inc. | METHODS FOR TREATMENT OF HYPOPHOSPHATASIA (HPP) IN ADULTS AND ADOLESCENTS |
EP3773684A1 (en) | 2018-03-30 | 2021-02-17 | Alexion Pharmaceuticals, Inc. | Manufacturing of glycoproteins |
JP2020015733A (ja) * | 2019-08-19 | 2020-01-30 | アンセルムInserm | 骨格成長遅延障害の予防または処置における使用のための、可溶性線維芽細胞増殖因子受容体3(fgr3)ポリペプチド |
EP4291224A1 (en) | 2021-02-12 | 2023-12-20 | Alexion Pharmaceuticals, Inc. | Alkaline phosphatase polypeptides and methods of use thereof |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5352770A (en) | 1990-04-20 | 1994-10-04 | Hisayuki Matsuo | Porcine derived novel physiologically active peptide |
JP2930380B2 (ja) | 1990-07-13 | 1999-08-03 | 壽之 松尾 | ブタ由来新規生理活性ペプチド(cnp―53) |
JP2977158B2 (ja) | 1990-09-07 | 1999-11-10 | 壽之 松尾 | トリ由来新規生理活性ペプチド(ニワトリcnp) |
JP2977159B2 (ja) | 1990-09-07 | 1999-11-10 | 壽之 松尾 | カエル由来新規生理活性ペプチド(カエルcnp) |
JP3026354B2 (ja) | 1990-09-27 | 2000-03-27 | 壽之 松尾 | ヒトcnp遺伝子及び前駆体蛋白 |
JP2809533B2 (ja) | 1991-01-31 | 1998-10-08 | 壽之 松尾 | Cnp類似体ペプチド |
EP1159423B1 (en) * | 1998-10-08 | 2005-03-09 | The University of Hong Kong | Uses of transgenic animals containing a type x collagen mutant |
IL142118A0 (en) | 2001-03-20 | 2002-03-10 | Prochon Biotech Ltd | Method and composition for treatment of skeletal dysplasias |
-
2002
- 2002-08-13 BR BRPI0203172A patent/BRPI0203172B8/pt not_active IP Right Cessation
- 2002-08-14 CA CA2398030A patent/CA2398030C/en not_active Expired - Lifetime
- 2002-08-14 CA CA2918219A patent/CA2918219A1/en not_active Abandoned
- 2002-08-14 US US10/218,109 patent/US6743425B2/en not_active Expired - Lifetime
-
2004
- 2004-04-20 US US10/827,341 patent/US20040198665A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
BRPI0203172B1 (pt) | 2016-02-23 |
CA2398030A1 (en) | 2003-03-28 |
US6743425B2 (en) | 2004-06-01 |
US20040198665A1 (en) | 2004-10-07 |
CA2398030C (en) | 2016-05-24 |
CA2918219A1 (en) | 2003-03-28 |
US20030068313A1 (en) | 2003-04-10 |
BRPI0203172B8 (pt) | 2021-05-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0203172A (pt) | Agentes terapêuticos para acondroplasia | |
TR200102967T2 (tr) | Substitüsyonlu azollar | |
BR0208150A (pt) | Antagonistas de mch e sua aplicação no tratamento da obesidade | |
BR0214343A (pt) | Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1 | |
ATE248837T1 (de) | Chinuclidin-acrylamide | |
DK0853083T3 (da) | Pyridylfuran- og piridylthiophenforbindelser og farmaceutisk anvendelse deraf | |
MY128654A (en) | Liquid pharmaceutical composition containing an erythropoietin derivative | |
IL178128A0 (en) | Salts of 3-0-(3',3'-dimethyl-succinyl) betulinic acid and pharmaceutical compositions containing the same | |
BR0210028A (pt) | Agentes antibacterianos | |
BR0010524A (pt) | Tratamento de tumores humanos refratários com antagonistas de receptor de fator de crescimento epidérmico | |
BR0312421A (pt) | Uso de inibidores de cept e opcionalmente inibidores hmg coa redutase e/ou agentes anti-hipertensivos | |
UY26851A1 (es) | Derivados de la 4-fenilpiridina | |
MXPA05007609A (es) | Antagonista de un receptor sensible al calcio. | |
BR0316723A (pt) | Derivados de anilinopirazol úteis para o tratamento de diabetes | |
BR0009472A (pt) | Antagonistas de lhrh com propriedades desolubilidade aperfeiçoadas | |
BR0213037A (pt) | Derivados de pirimidina | |
ES2422081T3 (es) | Péptido Ser-Ser-Ser-Arg y sus utilizaciones medicinales | |
DE60012890D1 (de) | Neue guanidin-derivate als zelladhäsion-inhibitoren | |
BR0317027A (pt) | Derivados de (2-amino-fenil)-amida de ácido arlileno-carboxìlico como agentes farmacêuticos | |
TW200519101A (en) | Benzimidazolone and quinazolinone derivatives as agonists on human ORL1 receptors | |
BR0113165A (pt) | Derivados de 4-pirimidinamina, composições farmacêuticas e métodos relacionados | |
BR0012327A (pt) | Pirrolidinas e piperidinas neurotróficas, e composições e métodos relacionados | |
BR0311642A (pt) | Formulação de divalproex de sódio de liberação aumentada | |
EP0861663A3 (en) | Osteoclastgenic inhibitory agent comprising interleukin-18 | |
MXPA05006889A (es) | Compuestos aromaticos como agentes anti-inflamatorios, inmunomoduladores y anti-proliferativos. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 23/02/2016, OBSERVADAS AS CONDICOES LEGAIS. |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 13/08/2002 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
B21A | Patent or certificate of addition expired [chapter 21.1 patent gazette] |
Free format text: PATENTE EXTINTA EM 13/08/2022 |